CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)] Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles-Global Forecast to 2030
세계의 CRISPR 시장 규모는 2025년 32억 1,000만 달러에서 2030년에는 54억 7,000만 달러에 달하며, CAGR은 11.2%로 대폭 상승할 것으로 예측됩니다.
| 조사 범위 |
| 조사 대상연도 |
2024-2030년 |
| 기준연도 |
2024년 |
| 예측 기간 |
2024-2030년 |
| 검토 단위 |
금액(10억 달러) |
| 부문 |
오퍼링별, 유형별, 최종사용자별, 서비스별, 용도별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
CRISPR 시장은 연구, 임상 및 산업 용도에서의 채택 확대가 두드러진 CAGR을 견인하며 큰 폭으로 성장하고 있습니다. 이러한 시장 성장에는 유전성 질환의 유병률 증가, 신약 개발 및 유전자 치료에서 CRISPR의 활용 확대, 생명공학 연구개발에 대한 투자 증가 등 여러 가지 요인이 기여하고 있습니다. 또한 CRISPR 툴의 발전, 전달 시스템의 개선, 규제 개선은 주류 연구 및 치료 파이프라인에 대한 통합을 더욱 가속화할 것입니다.
제품별로 CRISPR 시장은 제품 및 서비스의 두 가지 주요 부문으로 분류됩니다. 제품 부문에는 CRISPR 키트 및 효소, CRISPR 라이브러리, 기타 제품이 포함됩니다. 서비스 부문에는 gRNA 합성 및 세포주 개발, 스크리닝 및 검증, 기타 서비스가 포함됩니다.
사용자들은 지속적인 혁신, 신제품 출시, 표준화된 즉시 사용 가능한 키트에 대한 접근을 점점 더 많이 요구하고 있습니다. 이 제품들은 유전자 편집, 기능 유전체학, 치료법 개발에 적용하기 위해 학술, 임상 및 산업 연구 분야에서 널리 사용되고 있습니다. 이는 시장 성장을 가속하는 중요한 요소입니다.
용도별 부문은 신약 개발 및 개발, 농업, 기타 용도의 세 가지로 분류됩니다. 가장 큰 부문은 신약 개발 분야로, CRISPR 기술은 유전자와 질병, 약물의 기능 간의 연관성을 쉽게 파악할 수 있도록 초기 단계의 연구를 강화합니다. 이러한 접근 방식은 타임라인을 단축하고 성공 가능성을 높이는 데 도움이 됩니다. 또한 제약 및 생명공학 기업은 맞춤형 의료, 유전자 치료 및 기능 유전체학을 촉진하기 위해 CRISPR을 R&D 프로세스에 통합하여 CRISPR 기술의 활용을 강화하고 있습니다.
최종사용자별로 CRISPR 제품 시장은 제약 및 생명공학 기업, 학술 및 연구 기관, 기타 최종사용자로 구분되며, 2024년에는 제약 및 생명공학 기업이 시장을 장악할 것으로 예측됩니다. 이러한 우위는 세포 치료 및 유전자 치료에 대한 투자 증가, 표적 식별 및 검증을 위한 정밀한 유전자 툴에 대한 수요 증가에 기인합니다. 이들 기업은 CRISPR 기술에 크게 의존하고 있으며, 강력한 자금력으로 고급 맞춤형 CRISPR 제품을 대규모로 채택할 수 있으며, 시장 점유율을 더욱 확대하는 데 기여하고 있습니다.
시장은 지역별로 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 나뉩니다. 북미는 CRISPR 시장에서 가장 큰 점유율을 차지하고 있으며, 앞으로도 선두를 유지할 것으로 예측됩니다. 이러한 우위는 유명한 연구기관의 존재와 생명공학에 대한 막대한 투자에 기인합니다. 또한 미국에서는 최첨단 의학 연구, 맞춤의료, 정밀의료에 대한 중요성이 강조되고 있으며, 이는 북미에 경쟁 우위를 부여하고 있습니다. 유럽의 CRISPR 시장 역시 독일, 영국, 프랑스 등 국가들의 연구개발 노력 증가에 힘입어 꾸준한 성장세를 보이고 있습니다.
세계의 CRISPR 시장에 대해 조사했으며, 오퍼링별, 유형별, 최종사용자별, 서비스별, 용도별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 개요
제4장 주요 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 공급망 분석
- 밸류체인 분석
- 에코시스템 분석
- Porter's Five Forces 분석
- 규제 분석
- 가격 분석
- 특허 분석
- 2025-2026년의 주요 컨퍼런스와 이벤트
- 주요 이해관계자와 구입 기준
- 투자와 자금조달 시나리오
- AI가 CRISPR 시장에 미치는 영향
- 무역 분석
제6장 CRISPR 시장, 오퍼링별
제7장 CRISPR 제품 시장, 유형별
- 서론
- CRISPR 키트와 효소
- CRISPR 라이브러리
- 기타
제8장 CRISPR 제품 시장, 최종사용자별
- 서론
- 제약·바이오테크놀러지 기업
- 학술연구기관
- 기타
제9장 CRISPR 시장, 서비스별
제10장 CRISPR 서비스 시장, 최종사용자별
- 서론
- 제약·바이오테크놀러지 기업
- 학술연구기관
- 기타
제11장 CRISPR 시장, 용도별
제12장 CRISPR 시장, 지역별
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 기타
- 라틴아메리카
- 중동 및 아프리카
제13장 경쟁 구도
- 서론
- 주요 참여 기업의 전략/강점
- 매출 분석, 2020-2024년
- 시장 점유율 분석, 2024년
- 기업 평가 매트릭스 : 주요 참여 기업, 2024년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
- 경쟁 시나리오
- 기업 평가와 재무 지표
- 브랜드/제품 비교
제14장 기업 개요
- 주요 참여 기업
- THERMO FISHER SCIENTIFIC INC.
- MERCK KGAA
- AGILENT TECHNOLOGIES, INC.
- GENSCRIPT
- REVVITY
- LONZA
- DANAHER CORPORATION
- TAKARA BIO INC.
- CREATIVE BIOGENE
- FUJIAN SUNYBIOTECH CO., LTD.
- EDITCO
- CARIBOU BIOSCIENCES, INC.
- HERA BIOLABS
- ORIGENE TECHNOLOGIES, INC.
- CELLECTA, INC.
- 기타 기업
- MAMMOTH BIOSCIENCES, INC.
- APPLIED STEMCELL
- NEW ENGLAND BIOLABS
- TOOLGEN, INC.
- GENECOPOEIA, INC.
- TWIST BIOSCIENCE
- SYNTHEGO
- EGENESIS
- INSCRIPTA, INC.
- PRECISION BIOSCIENCES
제15장 부록
KSA
The global CRISPR market is anticipated to reach USD 5.47 billion by 2030 from USD 3.21 billion in 2025, at a significant CAGR of 11.2%.
| Scope of the Report |
|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD billion) |
| Segments | Offerings, Products, Services, Applications, and End Users |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
The CRISPR market is experiencing substantial growth, with a notable CAGR driven by its increasing adoption in research, clinical, and industrial applications. Several factors contribute to this market expansion, including the rising prevalence of genetic disorders, the growing use of CRISPR in drug discovery and gene therapy, and increased investments in biotechnology research and development. Additionally, advancements in CRISPR tools, improved delivery systems, and supportive regulatory developments further accelerate its integration into mainstream research and therapeutic pipelines.
"Products dominated the CRISPR market, by offering, in 2024."
Based on offerings, the CRISPR market is categorized into two main segments: products and services. The products segment includes CRISPR kits & enzymes, CRISPR libraries, and other products. The services segment encompasses gRNA synthesis & cell line development, screening & validation, and other services.
Users are increasingly seeking ongoing innovations, new product releases, and access to standardized, ready-to-use kits. These products are widely utilized in academic, clinical, and industrial research for applications in genome editing, functional genomics, and therapeutic development. This is a key factor driving market growth.
"The drug discovery & development application segment is anticipated to grow at a faster pace during the forecast period."
The application segment is divided into three categories: drug discovery & development, agriculture, and other applications. The largest segment is drug discovery & development, as CRISPR technology enhances early-stage research by facilitating the identification of connections between genes and diseases, as well as drug functions. This approach helps reduce timelines and increase the likelihood of success. Additionally, pharmaceutical & biotechnology companies are integrating CRISPR into their research and development processes to advance personalized medicine, gene therapy, and functional genomics, thereby enhancing the utilization of CRISPR technology.
"Pharmaceutical & biotechnology companies dominated the CRISPR products market, by end user, in 2024."
Based on end users, the CRISPR products market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, pharmaceutical & biotechnology companies dominated this market. This dominance is driven by increasing investments in cell and gene therapies, as well as the demand for precise genetic tools for target identification and validation. These companies rely heavily on CRISPR technologies, and their strong financial capacity allows them to adopt advanced and customized CRISPR products at scale, further contributing to their significant market share.
"North America accounted for the largest share of the CRISPR market in 2024."
The market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the CRISPR market and is expected to maintain its lead. This dominance is attributed to the presence of prominent research institutions and significant investments in biotechnology. Additionally, the growing emphasis on cutting-edge medical research, personalized medicine, and precision medicine in the US gives North America a competitive advantage. The European CRISPR market is also experiencing steady growth, fueled by increased research and development efforts, particularly in countries such as Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the CRISPR market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
- By Region: North America (35%), Europe (30%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
The prominent players operating in the CRISPR market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunyBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), Lonza Group (Switzerland), Danaher Corporation (US), Revvity, Inc. (US), Hera BioLabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), Twist Bioscience Corporation (US), Synthego Corporation (US), eGenesis (US), Inscripta, Inc. (US), and Precision BioSciences, Inc. (US), among others.
Research Coverage:
The CRISPR market report is segmented based on offerings [products (CRISPR kits & enzymes, CRISPR libraries, and other products), services (gRNA synthesis & cell line development, screening & validation, and other services)], applications (drug discovery & development, agriculture, and other applications), and end users [product (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and service (pharmaceutical & biotechnology companies, academic & research institutes, and other end users)].
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRISPR market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers new launches, collaborations, acquisitions, and recent developments associated with the CRISPR market.
Key Benefits of Buying the Report:
The report will assist both market leaders and new entrants by providing accurate revenue estimates for CRISPR and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to position their businesses effectively and develop suitable go-to-market strategies. Additionally, this report will allow stakeholders to gauge the market dynamics and offer insights into the key drivers, restraints, opportunities, and challenges within the market.
The report provides insights into the following pointers:
- Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, and growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases and expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the market.
- Product Development/Innovation: In-depth analysis of emerging technologies in CRISPR, R&D activities, and new product launches in the CRISPR market.
- Market Development: The report provides detailed information about profitable markets and analyzes the market conditions across various regions.
- Market Diversification: Comprehensive information about new products, unexplored regions, recent updates, and investments in the CRISPR market.
- Competitive Assessment: Comprehensive evaluation of market shares, growth strategies, and product & service offerings of leading companies such as Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), and GenScript (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY RESEARCH
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET ESTIMATION
- 2.2.1.1 Insights From Primary Experts
- 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
- 2.3 MARKET GROWTH RATE PROJECTION
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 CRISPR MARKET OVERVIEW
- 4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2024)
- 4.3 CRISPR MARKET SHARE, BY END USER, 2025 VS. 2030
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing demand for CRISPR-based gene therapies
- 5.2.1.2 Advancements in CRISPR technology
- 5.2.1.3 Growing government and private investments and funding for CRISPR technology
- 5.2.2 RESTRAINTS
- 5.2.2.1 Technical challenges associated with CRISPR technology
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Development of new vaccines and treatments for genetic diseases
- 5.2.3.2 Expanding industrial and agricultural applications of CRISPR
- 5.2.4 CHALLENGES
- 5.2.4.1 Regulatory hurdles for CRISPR advancements
- 5.2.5 TECHNOLOGY ANALYSIS
- 5.2.5.1 Key technologies
- 5.2.5.1.1 CRISPR-Cas systems
- 5.2.5.1.2 gRNA design & optimization
- 5.2.5.1.3 High-throughput CRISPR screening
- 5.2.5.2 Complementary technologies
- 5.2.5.2.1 Synthetic biology
- 5.2.5.2.2 Single-cell genomics
- 5.2.5.2.3 Next-generation sequencing
- 5.2.5.3 Adjacent technologies
- 5.2.5.3.1 Stem cell engineering
- 5.2.5.3.2 Synthetic DNA & gene synthesis
- 5.2.5.3.3 Microfluidics
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.4 SUPPLY CHAIN ANALYSIS
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 ECOSYSTEM ANALYSIS
- 5.7 PORTER'S FIVE FORCES ANALYSIS
- 5.7.1 THREAT OF NEW ENTRANTS
- 5.7.2 THREAT OF SUBSTITUTES
- 5.7.3 BARGAINING POWER OF BUYERS
- 5.7.4 BARGAINING POWER OF SUPPLIERS
- 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.8 REGULATORY ANALYSIS
- 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.8.2 REGULATORY FRAMEWORK
- 5.8.2.1 North America
- 5.8.2.1.1 US
- 5.8.2.1.2 Canada
- 5.8.2.2 Europe
- 5.8.2.2.1 Germany
- 5.8.2.2.2 UK
- 5.8.2.2.3 France
- 5.8.2.3 Asia Pacific
- 5.8.2.3.1 Japan
- 5.8.2.3.2 China
- 5.8.2.4 Latin America
- 5.8.2.5 Middle East & Africa
- 5.8.2.5.1 GCC Countries
- 5.8.2.5.2 South Africa
- 5.9 PRICING ANALYSIS
- 5.9.1 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
- 5.9.2 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022-2024
- 5.9.3 INDICATIVE PRICE TREND FOR CRISPR SERVICES
- 5.9.4 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024
- 5.10 PATENT ANALYSIS
- 5.11 KEY CONFERENCES & EVENTS, 2025-2026
- 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.12.2 CRISPR MARKET: BUYING CRITERIA
- 5.13 INVESTMENT & FUNDING SCENARIO
- 5.14 IMPACT OF AI ON CRISPR MARKET
- 5.15 TRADE ANALYSIS
- 5.15.1 IMPORT DATA FOR KITS & REAGENTS, 2019-2023
- 5.15.2 EXPORT DATA FOR KITS & REAGENTS, 2019-2023
- 5.15.3 TRUMP IMPACT OVERVIEW: CRISPR MARKET
- 5.15.3.1 Introduction
- 5.15.3.2 Key tariff rates
- 5.15.3.3 Price impact analysis
- 5.15.3.4 Key Impact on various regions
- 5.15.3.4.1 US
- 5.15.3.4.2 Europe
- 5.15.3.4.3 Asia Pacific
- 5.15.3.4.4 Rest of the World
- 5.15.3.5 End-use industry impact
- 5.15.3.5.1 Pharmaceutical & biotech companies
- 5.15.3.5.2 Contract research organizations (CROs)
- 5.15.3.5.3 Academic & research institutes
6 CRISPR MARKET, BY OFFERING
- 6.1 INTRODUCTION
- 6.2 PRODUCTS
- 6.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
- 6.3 SERVICES
- 6.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET
7 CRISPR PRODUCTS MARKET, BY TYPE
- 7.1 INTRODUCTION
- 7.2 CRISPR KITS & ENZYMES
- 7.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
- 7.3 CRISPR LIBRARIES
- 7.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH
- 7.4 OTHER PRODUCTS
8 CRISPR PRODUCTS MARKET, BY END USER
- 8.1 INTRODUCTION
- 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 8.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
- 8.3 ACADEMIC & RESEARCH INSTITUTES
- 8.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
- 8.4 OTHER END USERS
9 CRISPR MARKET, BY SERVICE
- 9.1 INTRODUCTION
- 9.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
- 9.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
- 9.1.2 SCREENING & VALIDATION
- 9.1.2.1 Rapid advancements in CRISPR technology to drive growth
- 9.2 OTHER SERVICES
10 CRISPR SERVICES MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 10.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
- 10.3 ACADEMIC & RESEARCH INSTITUTES
- 10.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
- 10.4 OTHER END USERS
11 CRISPR MARKET, BY APPLICATION
- 11.1 INTRODUCTION
- 11.2 DRUG DISCOVERY & DEVELOPMENT
- 11.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
- 11.3 AGRICULTURE
- 11.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
- 11.4 OTHER APPLICATIONS
12 CRISPR MARKET, BY REGION
- 12.1 INTRODUCTION
- 12.2 NORTH AMERICA
- 12.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
- 12.2.2 US
- 12.2.2.1 Increasing demand for CRISPR products and services across various industries to drive growth
- 12.2.3 CANADA
- 12.2.3.1 Increasing demand for gene-editing technologies to boost growth
- 12.3 EUROPE
- 12.3.1 MACROECONOMIC OUTLOOK OF EUROPE
- 12.3.2 GERMANY
- 12.3.2.1 Rapidly increasing biotechnology sector to support growth
- 12.3.3 UK
- 12.3.3.1 Significant government investments in genomics research to propel growth
- 12.3.4 FRANCE
- 12.3.4.1 Increasing demand for targeted therapies and personalized medicine to propel growth
- 12.3.5 ITALY
- 12.3.5.1 Increasing demand for innovative therapeutic solutions to drive growth
- 12.3.6 SPAIN
- 12.3.6.1 Increasing demand for precision medicine to drive growth
- 12.3.7 REST OF EUROPE
- 12.4 ASIA PACIFIC
- 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 12.4.2 CHINA
- 12.4.2.1 Increasing investments in R&D to drive growth
- 12.4.3 JAPAN
- 12.4.3.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
- 12.4.4 INDIA
- 12.4.4.1 Increasing prevalence of genetic disorders to support growth
- 12.4.5 REST OF ASIA PACIFIC
- 12.5 LATIN AMERICA
- 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 12.5.2 BRAZIL
- 12.5.2.1 Growing adoption of genome technologies to propel growth
- 12.5.3 REST OF LATIN AMERICA
- 12.6 MIDDLE EAST & AFRICA
- 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
- 13.1 INTRODUCTION
- 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET
- 13.3 REVENUE ANALYSIS, 2020-2024
- 13.4 MARKET SHARE ANALYSIS, 2024
- 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 13.5.1 STARS
- 13.5.2 EMERGING LEADERS
- 13.5.3 PERVASIVE PLAYERS
- 13.5.4 PARTICIPANTS
- 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 13.5.5.1 Company footprint
- 13.5.5.2 Region footprint
- 13.5.5.3 Product footprint
- 13.5.5.4 Service footprint
- 13.5.5.5 Application footprint
- 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 13.6.1 PROGRESSIVE COMPANIES
- 13.6.2 RESPONSIVE COMPANIES
- 13.6.3 DYNAMIC COMPANIES
- 13.6.4 STARTING BLOCKS
- 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
- 13.6.5.1 Detailed list of key startups/SMEs
- 13.6.5.2 Competitive benchmarking of key startups/SMEs
- 13.7 COMPETITIVE SCENARIO
- 13.7.1 PRODUCT LAUNCHES & APPROVALS
- 13.7.2 DEALS
- 13.7.3 EXPANSIONS
- 13.8 COMPANY VALUATION & FINANCIAL METRICS
- 13.9 BRAND/PRODUCT COMPARISON
14 COMPANY PROFILES
- 14.1 KEY PLAYERS
- 14.1.1 THERMO FISHER SCIENTIFIC INC.
- 14.1.1.1 Business overview
- 14.1.1.2 Products/Services offered
- 14.1.1.3 Recent developments
- 14.1.1.3.1 Product/Service launches
- 14.1.1.3.2 Deals
- 14.1.1.3.3 Expansions
- 14.1.1.4 MnM view
- 14.1.1.4.1 Key strengths
- 14.1.1.4.2 Strategic choices
- 14.1.1.4.3 Weaknesses & competitive threats
- 14.1.2 MERCK KGAA
- 14.1.2.1 Business overview
- 14.1.2.2 Products/Services offered
- 14.1.2.3 Recent developments
- 14.1.2.4 MnM view
- 14.1.2.4.1 Key strengths
- 14.1.2.4.2 Strategic choices
- 14.1.2.4.3 Weaknesses & competitive threats
- 14.1.3 AGILENT TECHNOLOGIES, INC.
- 14.1.3.1 Business overview
- 14.1.3.2 Products/Services offered
- 14.1.3.3 Recent developments
- 14.1.3.3.1 Deals
- 14.1.3.3.2 Expansions
- 14.1.3.4 MnM view
- 14.1.3.4.1 Key strengths
- 14.1.3.4.2 Strategic choices
- 14.1.3.4.3 Weaknesses & competitive threats
- 14.1.4 GENSCRIPT
- 14.1.4.1 Business overview
- 14.1.4.2 Products/Services offered
- 14.1.4.3 Recent developments
- 14.1.4.3.1 Product/service approvals/launches
- 14.1.4.3.2 Deals
- 14.1.4.3.3 Expansions
- 14.1.5 REVVITY
- 14.1.5.1 Business overview
- 14.1.5.2 Products/Services offered
- 14.1.5.3 Recent developments
- 14.1.6 LONZA
- 14.1.6.1 Business overview
- 14.1.6.2 Products/Services offered
- 14.1.6.3 Recent developments
- 14.1.7 DANAHER CORPORATION
- 14.1.7.1 Business overview
- 14.1.7.2 Products/Services offered
- 14.1.7.3 Recent developments
- 14.1.8 TAKARA BIO INC.
- 14.1.8.1 Business overview
- 14.1.8.2 Products/Services offered
- 14.1.8.3 Recent developments
- 14.1.9 CREATIVE BIOGENE
- 14.1.9.1 Business overview
- 14.1.9.2 Products/Services offered
- 14.1.9.3 Recent developments
- 14.1.9.3.1 Product/service approvals/launches
- 14.1.10 FUJIAN SUNYBIOTECH CO., LTD.
- 14.1.10.1 Business overview
- 14.1.10.2 Products/Services offered
- 14.1.11 EDITCO
- 14.1.11.1 Business overview
- 14.1.11.2 Products/Services offered
- 14.1.11.3 Recent financials
- 14.1.12 CARIBOU BIOSCIENCES, INC.
- 14.1.12.1 Business overview
- 14.1.12.2 Products/Services offered
- 14.1.12.3 Recent developments
- 14.1.13 HERA BIOLABS
- 14.1.13.1 Business overview
- 14.1.13.2 Products/Services offered
- 14.1.14 ORIGENE TECHNOLOGIES, INC.
- 14.1.14.1 Business overview
- 14.1.14.2 Products/Services offered
- 14.1.15 CELLECTA, INC.
- 14.1.15.1 Business overview
- 14.1.15.2 Products/Services offered
- 14.2 OTHER PLAYERS
- 14.2.1 MAMMOTH BIOSCIENCES, INC.
- 14.2.2 APPLIED STEMCELL
- 14.2.3 NEW ENGLAND BIOLABS
- 14.2.4 TOOLGEN, INC.
- 14.2.5 GENECOPOEIA, INC.
- 14.2.6 TWIST BIOSCIENCE
- 14.2.7 SYNTHEGO
- 14.2.8 EGENESIS
- 14.2.9 INSCRIPTA, INC.
- 14.2.10 PRECISION BIOSCIENCES
15 APPENDIX
- 15.1 DISCUSSION GUIDE
- 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 15.3 CUSTOMIZATION OPTIONS
- 15.4 RELATED REPORTS
- 15.5 AUTHOR DETAILS
